EFFICACY AND TOLERABILITY OF FIXED‐DOSE COMBINATIONS OF TELMISARTAN PLUS HCTZ COMPARED WITH LOSARTAN PLUS HCTZ IN PATIENTS WITH ESSENTIAL HYPERTENSION

Abstract

SUMMARYTelmisartan, an angiotensin II receptor blocker, is an effective once‐daily antihypertensive agent available either alone or in fixed‐dose combination with hydrochlorothiazide (HCTZ). This multicentre, prospective, randomised, open‐label, blinded‐endpoint (PROBE) study assessed the efficacy and safety of six weeks' treatment with telmisartan 40 mg/HCTZ 12.5 mg (n=199) and telmisartan 80 mg/HCTZ 12.5 mg (n=200) versus losartan 50 mg/HCTZ 12.5 mg (n=198) in patients with mild to moderate essential hypertension. During the last six hours of the dosing interval, telmisartan 40 mg/HCTZ 12.5 mg and telmisartan 80 mg/HCTZ 12.5 mg reduced mean ambulatory diastolic blood pressure (DBP) to a greater extent than losartan 50 mg/HCTZ 12.5 mg (treatment differences 1.8 mmHg [p<0.05] and 2.5 mmHg [p<0.001], respectively). Telmisartan 80 mg/HCTZ 12.5 mg also lowered mean 24‐hour DBP by 2.3 mmHg more than losartan 50 mg/HCTZ 12.5 mg (p<0.001). Telmisartan 40 mg/HCTZ 12.5 mg and telmisartan 80 mg/HCTZ 12.5 mg produced greater reductions in ambulatory systolic blood pressure versus losartan 50 mg/HCTZ 12.5 mg of 2.5 mmHg and 3.4 mmHg, respectively, during the last six hours of the dosing interval (p<0.05), and of 2.1 mmHg and 3.4 mmHg, respectively, over the entire 24‐hour dosing interval (p<0.05). All treatments were well tolerated.